.png)
Grandbrothers/iStock Editorial via Getty Images
- Jazz Pharmaceuticals (NASDAQ:JAZZ) has received the U.S. FDA's approval for Modeyso (dordaviprone), an orally administered once-weekly therapy for a rare brain tumor known as diffuse midline glioma, as a late-line option.
- Specifically, the agency has granted accelerated approval for Modeyso therapy
English (US) ·